To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Rilmenidine is a prescription medication administered to treat hypertension. It is marketed under the brand name HYPERIUM®.
Additional recommended knowledge
Form and composition
Each tablet contains 1.544 mg rilmenidine dihydrogen phosphate, an amount equivalent to 1 mg rilmenidine base.
Mode of action
Hyperium, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Hyperium shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists.
Severe depression, severe renal failure (creatinine clearance <15 ml/min), as a precaution in the absence of currently available studies.
Therapy should never be interrupted suddenly; the dosage should be reduced gradually.
Combinations not recommended: combination with MAOIs is not recommended; combination with tricyclic antidepressants requires prudence, as the antihypertensive activity of Hyperium may be partly antagonized.
Side-effects are rare, non-severe, and transient at therapeutic doses: asthenia, palpitations, insomnia, drowsiness, fatigue on exercise, epigastric pain, dryness of the mouth, diarrhea, skin rash; and exceptionally, cold extremities, postural hypotension, sexual disorders, anxiety, depression, pruritus, edema, cramps, nausea, constipation, hot flushes.
Dosage and route of administration
The recommended dosage is 1 tablet per day as a single morning administration. If results are not adequate after 1 month of treatment, the dosage may be increased to 2 tablets per day, given in divided doses (1 tablet morning and evening) before meals. As a result of its good clinical and biological acceptability, Hyperium may be administered to both elderly and diabetic hypertensive patients. In patients with renal failure, no dosage adjustment is necessary in principle when the creatinine clearance is greater than 15 mL/min.
Treatment may be continued indefinitely.
No cases of massive absorption have been reported. Likely symptoms in such an eventuality would be marked hypotension and lowered alertness. In addition to gastric lavage, sympathomimetic agents may also required. Hyperium is only slightly dialysable.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rilmenidine". A list of authors is available in Wikipedia.|